Brief: Anpac Bio Announces Equity Investment From Keystone Capital Partners For Up To $7 Million
Oct 1 (Reuters) - AnPac Bio-Medical Science Co Ltd ANPC.O :
* ANPAC BIO ANNOUNCES EQUITY INVESTMENT FROM KEYSTONE
CAPITAL
PARTNERS FOR UP TO $7 MILLION
* ANPAC BIO-MEDICAL SCIENCE CO LTD - ENTERED INTO AGREEMENT
WITH
KEYSTONE CAPITAL PARTNERS FOR A PREFERRED STOCK INVESTMENT OF
US$7.0 MILLION
* ANPAC BIO-MEDICAL - INVESTMENT PROVIDES CO WITH ADDITIONAL
ACCESS TO GROWTH CAPITAL TO EXPAND OPERATIONS IN CHINA, CONTINUE
TO COMMERCIALIZE IN U.S.
* ANPAC BIO-MEDICAL - INTENDS TO USE FUNDING PROCEEDS TO
ADVANCE
ITS CDA TECHNOLOGY TO PROVIDE COST-EFFECTIVE EARLY-DETECTION
CANCER SCREENING, TESTING
Source text for Eikon: ID:nGNX86GCkW
Further company coverage: ANPC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fresh2
See all newsBrief: Fresh2 Group On Dec 20, Received Nasdaq Notice That It Will Be Delisted From Nasdaq Capital Market Effective At Open Of Market On Dec 24
Brief: Fresh2 Group Ltd. Announces Receipt Of Staff Delisting Determination From Nasdaq Intends To Request A Hearing
Brief: Fresh2 Group Ltd Announces Receipt Of A Delinquency Compliance Alert Notice From Nasdaq
Brief: Anpac Bio-Medical Science - In Dec 2022 And Jan 2023, Signed Definitive Investment Agreements With Several Third Party Investors
Brief: AnPac Bio Granted Continued Listing By Nasdaq Hearing Panel, Subject To Meeting $1 Bid Price Compliance Rule On Or Before Nov. 23, 2022